Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, a modifier gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa (MENA) region.
According to Ocugen, the anticipated license agreement would provide up to $4 million in upfront and near-term development milestone payments, cumulative sales milestones up to $255 million, and a 22% royalty on net sales generated by its partner. Ocugen would also manufacture commercial supply of OCU400 under a related supply agreement. The company continues to advance OCU400 in its Phase 3 liMeliGhT trial, with topline data expected in 1Q 2027 followed by a planned BLA submission. Execution of the definitive agreement is expected within 90 days.
Positive
- Upfront and near-term milestones up to $4 million from MENA license
- Sales milestone potential up to $255 million tied to OCU400 net sales
- Royalty rate of 22% on OCU400 net sales in the MENA region
- Manufacturing role as Ocugen to supply commercial OCU400 under a supply agreement
- Geographic expansion via exclusive OCU400 licensing strategy in the MENA market
Negative
- Term sheet stage: definitive OCU400 license agreement still pending execution within 90 days
- Regulatory timeline: Phase 3 topline for OCU400 only expected in 1Q 2027 before BLA filing
News Explained
Ocugen has potential regional licensing revenue and a manufacturing role, but definitive agreements and related economics remain pending.
On
If the license and related supply agreement are executed, Ocugen would receive upfront and near-term development milestones totaling up to
The disclosed payment amounts are potential ceilings and future contract economics, rather than cash proceeds identified as received in this release.
The definitive agreement is expected within the next
Market reaction: OCGN -4.08% on OCU400 MENA licensing partnership
On the day this news was published, OCGN declined 4.08%, reflecting a moderate negative market reaction. This price movement removed approximately $21M from the company's valuation, bringing the market cap to $497.63M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 01 | Conference participation | Neutral | -3.3% | Announcement of participation in multiple July ophthalmology conferences. |
| Jun 02 | Conference participation | Neutral | -2.2% | June investor and industry conference schedule highlighting gene therapy platform. |
| May 14 | Debt financing | Positive | -4.8% | Closing of $130M 6.75% convertible senior notes due 2034 financing. |
| May 13 | Conference participation | Neutral | +0.0% | May scientific and investor presentations on modifier gene therapy platform. |
| May 05 | Earnings report | Positive | -19.5% | Q1 2026 results with OCU410 data and late-stage program updates. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Ocugen headlines, including financings and updates, have often been followed by negative price reactions regardless of generally neutral-to-positive content.
Key Terms
binding term sheet financial
modifier gene therapy medical
retinitis pigmentosa medical
phase 3 medical
topline readout technical
bla submission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Cumulative sales milestones up to
$255 million and modest upfront/near-term development milestones - Royalties equaling
22% of net sales - Ocugen to manufacture and supply OCU400
MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.
Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone payments totaling up to
RP is a leading cause of inherited vision loss globally, with notable prevalence across the MENA region, underscoring the significant unmet need OCU400 is positioned to address through this partnership.
"This step forward represents an important milestone in our effort to advance OCU400 regional partnership strategy," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "By partnering with an established leader with strong reach across the Middle East and North Africa, we are expanding our ability to bring this one-time potential treatment for life to a region where RP is highly prevalent with a significant unmet medical need where patients are desperately looking for rescue from blindness. This agreement underscores the momentum behind OCU400 and our continued commitment to patients."
“Bringing innovative gene therapies to patients across the MENA region is a strategic imperative for Roots Pharmaceutical and its strategic partner Al-Dhow International Holding,” said Dr. Islam Zayed, CEO & Co founder of Roots Pharmaceutical. Dr.Zayed emphasized that “ OCU400 built on our legacy of bringing Rare Disease therapies to patients in MENA and enables our combined teams to decrease disease burden in the region. Importantly, Roots is dedicated to bringing OCU400 to patients with Retinitis Pigmentosa and creating a new treatment paradigm. We are excited to partner with the Ocugen team.”
Additional details will be available once the definitive agreement between the parties is executed, which is expected to occur within the next 90 days.
Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the terms of the definitive license and supply agreement with Roots Pharmaceutical, the timing of entering into such definitive agreement or whether such definitive agreement will be executed at all, the anticipated benefits to Ocugen of such definitive agreement, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that the definitive license and supply agreement with Roots Pharmaceutical will be delayed or not executed at all, or that, if executed, it will not be on terms described above, the risk that such definitive agreement, if executed, will not lead to the currently anticipated benefits to Ocugen, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
